Oracle Investment Management’s Novavax NVAX Stock Holding History

Oracle Investment Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-243,000	Closed	-$2.11M	–	26
2025 Q3	$2.11M	Buy	+243,000	New	+$1.89M	1.32%	13

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oracle Investment Management's NVAX Position: Q4 2025 in Review

Oracle Investment Management sold out of Novavax (NVAX) in Q4 2025, closing a stake of 243,000 shares — an estimated $2.11M sold.

Oracle Investment Management first reported a position in NVAX in Q3 2025 and held it in 1 quarter. The position peaked at $2.11M in Q3 2025. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

Oracle Investment Management reported no remaining Novavax position as of Q4 2025 after selling out during the quarter.
Oracle Investment Management sold 243,000 Novavax shares in Q4 2025, an estimated $2.11M.
Oracle Investment Management first reported a position in Novavax in Q3 2025 and held it in 1 quarter.
Oracle Investment Management's Novavax position peaked at $2.11M in Q3 2025.
235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Oracle Investment Management's 13F filing for Q4 2025, filed 18 Feb 2026.